Within the phase 2 program for faldaprevir, SILEN-C3 was designed to investigate the efficacy and safety of response-guided faldaprevir at 120 mg for 12 weeks versus 24 weeks, while the randomized, double-blind SILEN-C1 study compared faldaprevir plus PegIFN/RBV treatment to PegIFN/RBV alone (14).
Secondary objectives included the evaluation of safety, duration of response, PFS and overall survival.
The primary end point was tumour response; secondary end points were safety, duration of response, time to progression and survival.
All three groups are concerned with efficacy, safety, sustainability of response to treatment or disease activity status.
More and more data have accumulated over recent years in regard to long-term efficacy and safety, prediction of response, and the relevance of extrarheumatic manifestations such as uveitis, psoriasis, and inflammatory bowel disease for treatment decisions with TNF blockers.
Briefly, BIOBADASER is a registry established in February 2000 for the active long-term follow-up and assessment of the safety of biological response modifiers in rheumatic patients.
Other studies have similarly used a systematic approach to local and international incidents and derived high-quality evidence and identified recurrent systematic problems that may improve the quality and safety of future response [ 19, 20, 23, 114].
Objective: To compare oil of evening primrose (OEP) and topical nonsteroidal anti-inflammatory (NSAIDs) with respect to safety, effectiveness, rapidity of response, cost effectiveness and acceptability in the treatment of breast pain.
This 28-week, phase IIIb study assessed safety and maintenance of response to certolizumab pegol (CZP) in a diverse population of rheumatoid arthritis (RA) patients, stratified by prior anti-TNF exposure, concomitant methotrexate (MTX) use and disease duration.
The three studies with results included: Safety and Efficacy of Vilazodone in Major Depressive Disorder; Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder; and Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD).
Recently, systematic relearning of safety in response to both internal and external phobic cues, with particular emphasis on altering responses to emotional arousal, has been highlighted as the central element of efficacious treatment for panic disorder [ 41].
